Carl Icahn is getting more interested in biotech, notably Bristol-Myers Squibb (NYSE:BMY). For starters, Icahn has a stake in BMY, although it's unclear how much. And now he has brought on a biotech expert to help run his fund. Icahn hired Harvard geneticist Richard Mulligan as a portfolio manager. Mulligan has worked with Icahn in the past, and was a managing director at Icahn protege Alex Denner's Sarissa Capital for the last three years.
The hire signals that Icahn is ready to formally take on the beaten-down biotech space. The iShares Nasdaq Biotech ETF (NASDAQ:IBB) is down some 12% in the last 24 months, while the S&P 500 is up 13%. Meanwhile, BMY has also been an underperformer, with shares down 5% in the same period. The thesis is that the $100 billion drug company might be a buyout target. Generally, the focus is on selling off smaller companies to the larger ones, but Icahn is aiming high here. This comes after Denner left Icahn's firm in 2013.

